VTE risk-prediction formula gains validation

Major finding: A validation analysis confirmed a venous thromboembolism risk-assessment formula as sensitive and specific for predicting VTE.

Data source: A retrospective case-control study with 417 cases and controls from a single Canadian health system.

Disclosures: Dr. Mahan said that he has been a consultant to or speaker for several drug companies including Janssen, Sanofi-Aventis, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer.